Lilly Oncology Medical (@LillyOncMed) “🔬 FRAmework-01 | Now Enrolling A phase 3 trial evaluating a FRα-targeting ADC i” — TopicDigg
Lilly Oncology Medical
@LillyOncMed
Dedicated to communicating the latest science & disease state education from Lilly Oncology. Intended for U.S. HCPs. Community Guidelines:
加入 March 2022
597 正在关注 6.6K 粉丝
🔬 FRAmework-01 | Now Enrolling
A phase 3 trial evaluating a FRα-targeting ADC in patients with Ovarian Cancer.
Key details:
- Enrolling PSOC and PROC
- All FRα expression levels
- Allows prior mirvetuximab
Click the image for trial & enrollment info
显示更多
